gen-1124
Small moleculeexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Apr 4, 2023 (NCT05795465)
Timeline
Indications
Mechanism of action
- MAP kinase ERK1MODULATOR
MAPK3 modulator
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07185113 | Phase 1 | Sep 30, 2025 | GEn1E Lifesciences, InClin, Inc. |
| NCT05795465 | Phase 2 | Apr 4, 2023 | GEn1E Lifesciences |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GEn1E Lifesciences | For profit | 2 | 2 | 2 | 2023 |
| InClin, Inc. | For profit | 1 | 0 | 1 | 2025 |
2 organizations
Page 1 / 1